Tom reports and edits European consumer health care industry news and analysis. Leading HBW Insight’s health and wellness coverage in Europe, he has been writing about the sector since 2013. Tom’s main focus is analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios. He also reports on regulatory topics such as novel foods and prescription-to-OTC switches.
Latest from Tom Gallen
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.
Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.
Supplements already under close scrutiny in the EU have been linked to severe adverse effects on the musculoskeletal system and liver, even at low doses.
Australia's SFI Health looking to take Equazen omega-3 fatty acids supplement to new markets to capitalize on Europe's fast-growing brain health segment.
Start-ups and individuals working on innovative consumer health concepts, in categories such as pain relief and dietary supplements, have the opportunity to access Haleon's resources and expertise to make their ideas a reality.
In its first health claim assessment of 2025, the European Commission has rejected an application by Sweden's Greenleaf for its Appethyl supplement.